Actelion’s clinical development activities include the characterization of macitentan in specific PAH patient populations as well as expanding its use beyond PAH. The pipeline also includes a S1P1 receptor modulator, ponesimod, investigated in multiple sclerosis.

Phase Compound Indication Study Status
Phase III Macitentan Pediatric PAH TOMORROW Initiating
Macitentan Portopulmonary hypertension (PoPH) PORTICO Ongoing
Macitentan Fontan-palliated RUBATO Initiating
Ponesimod Multiple sclerosis OPTIMUM Ongoing
Ponesimod Multiple sclerosis POINT Ongoing
Selexipag Short-term replacement of IV selexipag IV selexipag Ongoing
Phase II Macitentan Chronic thromboembolic pulmonary hypertension MERIT Ongoing


"I enjoy working for Actelion because every day we strive to make a difference in people's lives."

Physician, Global Drug Safety